References
- Al Rawahi T, Lopes AD, Bristow RE, et al (2013). Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev, 2013, 2.
- Arikan SK, Kasap B, Yetimalar H, et al (2014). Impact of prognostic factors on survival rates in patients with ovarian carcinoma. Asian Pac J Cancer Prev, 15, 6087-94. https://doi.org/10.7314/APJCP.2014.15.15.6087
- Benedet JL, Bender H, Jones 3rd H, et al (2000). FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet, 70, 209-62. https://doi.org/10.1016/S0020-7292(00)90001-8
- Bristow RE, Tomacruz RS, Armstrong DK, et al (2002). Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol, 20, 1248-59. https://doi.org/10.1200/JCO.20.5.1248
- Chi DS, Eisenhauer EL, Lang J, et al (2006). What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol, 103, 559-64. https://doi.org/10.1016/j.ygyno.2006.03.051
- Eisenkop SM, Friedman RL, Spirtos NM (2000). The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer, 88, 144-53. https://doi.org/10.1002/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO;2-X
- Fotopoulou C, Richter R, Braicu IE, et al (2011). Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer. Ann Surg Oncol, 18, 49-57. https://doi.org/10.1245/s10434-010-1245-3
- Fotopoulou C, Zang R, Gultekin M, et al (2013). Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation. Ann Surg Oncol, 20, 1348-54. https://doi.org/10.1245/s10434-012-2673-z
- Gultekin M, Velipasaoglu M, Aksan Guldeniz, et al (2008). A Third Evaluation of Tertiary Cytoreduction. J Surgical Oncol, 98, 530-4. https://doi.org/10.1002/jso.21146
- Harter P, du Bois A, Hahmann M, et al ( 2006). Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol, 13, 1702-10. https://doi.org/10.1245/s10434-006-9058-0
- Hizli D, Boran N, Yilmaz S, et al (2012). Best predictors of survival outcome after tertiary cytoreduction in patients with recurrent platinum-sensitive epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol, 163, 71-5. https://doi.org/10.1016/j.ejogrb.2012.03.018
- Karam AK, Santillan A, Bristow RE, et al (2007). Tertiary cytoreductive surgery in recurrent ovarian cancer: Selection criteria and survival outcome. Gynecol Oncol, 104, 377-80. https://doi.org/10.1016/j.ygyno.2006.08.037
- Leitao MM, Kardos S, Barakat RR, et al (2004). Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecol Oncol, 95, 181-8. https://doi.org/10.1016/j.ygyno.2004.07.033
- Maldonado G, Greenland S (1993). Simulation study of confounder-selection strategies. Am J Epidemiol, 138, 923-36. https://doi.org/10.1093/oxfordjournals.aje.a116813
- Sehouli J, Richter R, Braicu EI, et al (2010). Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. J Surg Oncol, 102, 656-62. https://doi.org/10.1002/jso.21652
- Shih KK, Chi DS, Barakat RR, et al (2010). Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series. Gynecol Oncol, 117, 330-5. https://doi.org/10.1016/j.ygyno.2010.01.046
- Tang J, Liu LD, Shu S, et al (2013). Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: Implications for tertiary cytoreductive surgery. EJSO, 39, 786-91. https://doi.org/10.1016/j.ejso.2013.02.006
- Zang RY, Li ZT, Tang J, et al (2004). Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer, 100, 1152-61. https://doi.org/10.1002/cncr.20106